Skip to content
2000
Volume 19, Issue 37
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612811319370009
2013-11-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612811319370009
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test